BR0209074A - Derivados de octreotìdeos glicosilados radioativos marcadores com tc e re - Google Patents

Derivados de octreotìdeos glicosilados radioativos marcadores com tc e re

Info

Publication number
BR0209074A
BR0209074A BR0209074-0A BR0209074A BR0209074A BR 0209074 A BR0209074 A BR 0209074A BR 0209074 A BR0209074 A BR 0209074A BR 0209074 A BR0209074 A BR 0209074A
Authority
BR
Brazil
Prior art keywords
ligands
peptide
sst
group
radioactive
Prior art date
Application number
BR0209074-0A
Other languages
English (en)
Inventor
Hans-Jurgen Wester
Margret Schottelius
Markus Schwaiger
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of BR0209074A publication Critical patent/BR0209074A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"DERIVADOS DE OCTREOTìDEOS GLICOSILADOS RADIOATIVOS MARCADORES COM Tc E Re". A presente invenção refere-se a ligandos peptídicos melhorados que se aglutinam a receptores sst para aplicações de diagnósticos e terapêuticas na medicina nuclear. Os ligandos melhorados contêm aminoácidos naturais ou não naturais ou estruturas peptideo miméticas que são modificadas na extremidade N-terminal ou C-terminal ou em ambos os terminais, uma unidade de carboidrato e um quelante ou grupo prostético para fornecer uma complexação de um radioisótopo que se liga ou que sustenta o radioisótopo. Os ligandos peptídicos que se ligam ao receptor sst ou SSTR podem conter ainda uma ou mais unidades ligantes multifuncionais que acoplam opcionalmente o peptídeo e/ou o grupamento de açúcar e/ou o quelante e/ou o grupo prostético. Após a administração do ligando a um mamífero através do sistema sang³íneo o ligando fornece maior disponibilidade, cinética de eliminação, direcionamento e internalização do receptor sst sobre os ligandos que não são carboidratados.
BR0209074-0A 2001-04-23 2002-04-23 Derivados de octreotìdeos glicosilados radioativos marcadores com tc e re BR0209074A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01201466 2001-04-23
PCT/US2002/012565 WO2002085418A2 (en) 2001-04-23 2002-04-23 Tc and re labeler radioactive glycosylated octreotide derivatives

Publications (1)

Publication Number Publication Date
BR0209074A true BR0209074A (pt) 2004-08-10

Family

ID=8180193

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209074-0A BR0209074A (pt) 2001-04-23 2002-04-23 Derivados de octreotìdeos glicosilados radioativos marcadores com tc e re

Country Status (11)

Country Link
US (2) US7589061B2 (pt)
EP (1) EP1381396B1 (pt)
JP (3) JP5398945B2 (pt)
AT (1) ATE427125T1 (pt)
AU (1) AU2002254691B8 (pt)
BR (1) BR0209074A (pt)
CA (1) CA2443273C (pt)
CZ (1) CZ20032872A3 (pt)
DE (1) DE60231801D1 (pt)
HU (1) HU228811B1 (pt)
WO (1) WO2002085418A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7956165B2 (en) 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
IL157086A0 (en) * 2003-07-24 2004-02-08 Guy Patchornik Multivalent ligand complexes
CN102253174A (zh) * 2011-04-27 2011-11-23 江苏省原子医学研究所 一种受体显像剂标记的化学动力学研究的方法
WO2013032012A1 (ja) * 2011-09-04 2013-03-07 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
RU2624034C2 (ru) 2011-09-04 2017-06-30 Глитек, Инк. Гликозилированные полипептиды и лекарственные композиции, содержащие данные полипептиды
AU2014396468B2 (en) * 2014-06-06 2019-02-21 Technische Universitat Munchen Modified cyclopentapeptides and uses thereof
JP7084417B2 (ja) 2017-01-12 2022-06-14 ラジオメディックス インコーポレイテッド 放射性同位体にキレートされたオクトレオチド誘導体を用いるソマトスタチン受容体を過剰発現しているがん細胞の治療
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU906340D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
JP2544159B2 (ja) 1987-10-07 1996-10-16 ハウス食品株式会社 連続蒸煮装置
MY106120A (en) 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
US5590656A (en) * 1992-09-15 1997-01-07 The Ohio State University Research Foundation Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
JPH10512852A (ja) 1994-12-07 1998-12-08 ネオルクス コーポレイション 放射性標識化アネキシン−ガラクトースクラスター複合体
CA2206274C (en) 1994-12-07 2009-06-30 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
US5753206A (en) * 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
EP0888381A4 (en) 1995-12-21 2001-10-17 Scripps Research Inst TARGETED THERAPEUTIC AND DIAGNOSTIC AGENTS, METHODS FOR THEIR PRODUCTION AND USE
DE19654764A1 (de) 1996-12-30 1998-07-02 Boehringer Mannheim Gmbh Verfahren zur Herstellung eines Peptidgemisches
EA200001007A1 (ru) 1998-03-31 2001-04-23 Дюпон Фармасьютикалз Компани Фармацевтические препараты для визуализации ангиогенных расстройств
DE19910419A1 (de) 1999-03-10 2000-09-21 Aventis Pharma Gmbh Zielzellspezifische, multivalente Proteine (MVP)

Also Published As

Publication number Publication date
WO2002085418A3 (en) 2003-09-12
CA2443273C (en) 2011-09-27
HUP0303987A3 (en) 2010-03-29
HU228811B1 (hu) 2013-05-28
JP5398945B2 (ja) 2014-01-29
HUP0303987A2 (hu) 2004-03-01
JP2005514321A (ja) 2005-05-19
EP1381396A2 (en) 2004-01-21
US20090324497A1 (en) 2009-12-31
ATE427125T1 (de) 2009-04-15
EP1381396B1 (en) 2009-04-01
JP2010001313A (ja) 2010-01-07
CZ20032872A3 (cs) 2005-01-12
CA2443273A1 (en) 2002-10-31
AU2002254691B2 (en) 2007-06-14
JP2013100349A (ja) 2013-05-23
US20060165593A1 (en) 2006-07-27
DE60231801D1 (de) 2009-05-14
US8575100B2 (en) 2013-11-05
US7589061B2 (en) 2009-09-15
WO2002085418A2 (en) 2002-10-31
AU2002254691B8 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
Béhé et al. Cholecystokinin‐B (CCK‐B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK‐B receptor expressing malignancies
Hoffman et al. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells
Kumagai et al. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport.
EP0630265B1 (en) TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING INFLAMMATION
FI117424B (fi) Peptidejä
WO1999000150A2 (en) Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
WO1989010134A1 (en) Chimeric peptides for neuropeptide delivery through the blood-brain barrier
Lin et al. Effects of chelator modifications on 68 Ga-labeled [Tyr 3] octreotide conjugates
JP2008517917A (ja) 癌を治療するための毒素および放射性核種結合ｉｇｆ−１受容体リガンド
Tolmachev et al. Targeted nuclear medicine. Seek and destroy
BR0209074A (pt) Derivados de octreotìdeos glicosilados radioativos marcadores com tc e re
Tran et al. Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging
US5082928A (en) Method of preparing conjugated antibodies
Tolmachev et al. Closo-dodecaborate (2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution
WO2022112323A1 (en) Stable formulations for radionuclide complexes
Zoghi et al. Development of a 68 Ga-peptide tracer for PET GnRH1-imaging
Verbeke et al. Technetium-99m mercaptoalbumin as a potential substitute for technetium-99m labelled red blood cells
Trachsel et al. Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK
AU2002254691A1 (en) Tc and Re labeler radioactive glycosylated octreotide derivatives
Aloj et al. Radiolabeling approaches for cholecystokinin B receptor imaging
US5208008A (en) Regioselective chemical modification of monoclonal antibodies
Ramjeesingh et al. Antigen protection of monoclonal antibodies undergoing labelling
Blok et al. Monoclonal Antibodies in Radioimmunoscintigraphy Some hurdles between clone and clinic
JPH05501107A (ja) 画像用放射標識抗体

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MALLINCKRODT LLC (US)

Free format text: NOME ALTERADO DE: MALLINCKRODT INC.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.